-
Notice of AGM & Annual Report & Accounts
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, confirms that the Notice of Annual General Meeting (“AGM”) has been posted to shareholders. The Annual Report and Accounts for the year ended 31 December 2021 will be posted to shareholders on 6 June 2022. These documents will be available shortly, in electronic…
-
FINAL RESULTS ANNOUNCEMENT for the year ended 31 December 2021
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2021 (the “Period”). Key Highlights (including post Period review) Loss for the Period of £8.2m (£6.9m at 31 December 2020) Research and development expenses of £3.7m (31 December 2020: £2.4m)…
-
UPDATE on LUPUZOR™ – POSITIVE PROGRESS to PHASE 3 with AVION
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to confirm that final preparations are now underway to progress Lupuzor™ into its new optimised international Phase 3 trial of Lupuzor™ in lupus patients. Further to the recent positive results from the Lupuzor™/P140 Pharmacokinetic (“PK”) study announced on 13 April 2022, we are…
-
UPDATE on P140 (LUPUZOR™) clinical progress. Data confirms positive readout from P140 PK study.
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to provide positive data from the Lupuzor™/P140 pharmacokinetic (“PK”) study, required by the US Food & Drug Administration (”FDA”), as part of the new optimised international Phase 3 trial of Lupuzor™ in lupus patients. Key highlights Data successfully demonstrates the PK study has…
-
LUPUZOR™ UPDATE. PK study commencement approved by MHRA – patient dosing to commence imminently
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to provide an update on the Lupuzor™ pharmacokinetic (“PK”) study, as part of the new optimised international Phase 3 trial of Lupuzor™ in Lupus patients. Key highlights Medical and Health Products Regulatory Agency (“MHRA”) approves commencement of the PK study Volunteers have been…
-
TR1 – Avion Pharmaceuticals – Major Holdings in Shares (10 January 2022)
TR-1: Standard form for notification of major holdings To view notification click here
-
TR1 – Luca Associates – Major Holdings in Shares (4 January 2022)
TR-1: Standard form for notification of major holdings To view notification click here
-
TR1 – Lanstead – Major Holding in Shares
TR-1: Standard form for notification of major holdings To view notification click here
-
Subscriptions and Placing to raise £3.55 million; Sharing Agreement; to fund Investment in R&D pipeline • Company’s Partner Alora and two longstanding investors including Lanstead to participate at an Issue price of 11p – 80% premium to current share price
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce subscriptions and a placing to raise £3.55 million (the “Subscription(s)” and “Placing”) through the issue of 32,272,727 new ordinary shares of 10 pence each in the Company (“Ordinary Shares”) at a price of 11 pence per Ordinary Share (“Issue…
-
Collaboration with Imperial College London
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is very pleased to announce that it has signed a 2-year collaboration agreement with Imperial College London. Under the collaboration, Imperial College will provide significant intellectual input and guidance on a number of innovative peptide assets being developed at our R&D subsidiary, ImmuPharma Biotech in Bordeaux.…
